<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pone.0199453.t004" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1371/journal.pone.0199453.t004</object-id>
 <label>Table 4</label>
 <caption>
  <title>Sensitivity analyses.</title>
  <p>Impact and cost-effectiveness of Zimbabwe’s VMMC program under alternative assumptions for key parameters whose values are uncertain.</p>
 </caption>
 <alternatives>
  <graphic id="pone.0199453.t004g" xlink:href="pone.0199453.t004" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="left" rowspan="2" colspan="1">Scenario</th>
     <th align="center" colspan="3" rowspan="1">Infections averted</th>
     <th align="center" colspan="3" rowspan="1">Cost
      <xref ref-type="table-fn" rid="t004fn002">
       <sup>a</sup>
      </xref> per infection averted
     </th>
    </tr>
    <tr>
     <th align="center" rowspan="1" colspan="1">Goals
      <xref ref-type="table-fn" rid="t004fn003">
       <sup>b</sup>
      </xref>
     </th>
     <th align="center" rowspan="1" colspan="1">ICL
      <xref ref-type="table-fn" rid="t004fn004">
       <sup>c</sup>
      </xref>
     </th>
     <th align="center" rowspan="1" colspan="1">EMOD
      <xref ref-type="table-fn" rid="t004fn003">
       <sup>b</sup>
      </xref>
     </th>
     <th align="center" rowspan="1" colspan="1">Goals
      <xref ref-type="table-fn" rid="t004fn003">
       <sup>b</sup>
      </xref>
     </th>
     <th align="center" rowspan="1" colspan="1">ICL
      <xref ref-type="table-fn" rid="t004fn004">
       <sup>c</sup>
      </xref>
     </th>
     <th align="center" rowspan="1" colspan="1">EMOD
      <xref ref-type="table-fn" rid="t004fn003">
       <sup>b</sup>
      </xref>
     </th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td align="left" rowspan="1" colspan="1">
      <bold>Default / best estimate</bold>
      <xref ref-type="table-fn" rid="t004fn005">
       <sup>d</sup>
      </xref>
     </td>
     <td align="center" rowspan="1" colspan="1">
      <bold>171,000</bold>
     </td>
     <td align="center" rowspan="1" colspan="1">
      <bold>128,000</bold>
     </td>
     <td align="center" rowspan="1" colspan="1">
      <bold>108,000</bold>
     </td>
     <td align="center" rowspan="1" colspan="1">
      <bold>$2,100</bold>
     </td>
     <td align="center" rowspan="1" colspan="1">
      <bold>$2,700</bold>
     </td>
     <td align="center" rowspan="1" colspan="1">
      <bold>$3,250</bold>
     </td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">HIV infections averted and costs discounted at 3% per year from 2015</td>
     <td align="center" rowspan="1" colspan="1">131,000</td>
     <td align="center" rowspan="1" colspan="1">96,000</td>
     <td align="center" rowspan="1" colspan="1">81,000</td>
     <td align="center" rowspan="1" colspan="1">$2,400</td>
     <td align="center" rowspan="1" colspan="1">$3,200</td>
     <td align="center" rowspan="1" colspan="1">$3,700</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">VMMC coverage at 2016 according to the 2015 DHS (14%) rather than the program estimate (28%)
      <xref ref-type="table-fn" rid="t004fn006">
       <sup>e</sup>
      </xref>
     </td>
     <td align="center" rowspan="1" colspan="1">156,000</td>
     <td align="center" rowspan="1" colspan="1">120,000</td>
     <td align="center" rowspan="1" colspan="1">104,000</td>
     <td align="center" rowspan="1" colspan="1">$2,200</td>
     <td align="center" rowspan="1" colspan="1">$2,100</td>
     <td align="center" rowspan="1" colspan="1">$3,300</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Add VMMC protective efficacy reducing M-to-F transmission by 46%</td>
     <td align="center" rowspan="1" colspan="1">287,000</td>
     <td align="center" rowspan="1" colspan="1">Not evaluated</td>
     <td align="center" rowspan="1" colspan="1">Not evaluated</td>
     <td align="center" rowspan="1" colspan="1">$1,200</td>
     <td align="center" rowspan="1" colspan="1">Not evaluated</td>
     <td align="center" rowspan="1" colspan="1">Not evaluated</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">EMOD with VMMC targeted across the male population aged 15–49 years</td>
     <td align="center" colspan="2" rowspan="1">NA / as default</td>
     <td align="center" rowspan="1" colspan="1">101,000</td>
     <td align="center" colspan="2" rowspan="1">NA / as default</td>
     <td align="center" rowspan="1" colspan="1">$3,600</td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="t004fn001">
   <p>The results shown are for the scenario in which the program targets for 2021 are achieved in a 'status quo' context, with impact evaluated over 2009–2030.</p>
  </fn>
  <fn id="t004fn002">
   <p>
    <sup>a</sup> Cost is direct VMMC program cost, not considering savings from ART averted
   </p>
  </fn>
  <fn id="t004fn003">
   <p>
    <sup>b</sup> Outcomes are for all ages
   </p>
  </fn>
  <fn id="t004fn004">
   <p>
    <sup>c</sup> Outcomes are for ages 15–49 only
   </p>
  </fn>
  <fn id="t004fn005">
   <p>
    <sup>d</sup> Default assumptions: No discounting, 2016 VMMC coverage at 28% per program service delivery statistics, VMMC protective efficacy on female-to-male transmission 60% per sex act, no direct effect of VMMC on male-to-female transmission
   </p>
  </fn>
  <fn id="t004fn006">
   <p>
    <sup>e</sup> See additional detailed results for other scale-up scenarios and time horizons in Section E in 
    <xref ref-type="supplementary-material" rid="pone.0199453.s001">S1 File</xref>.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
